FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2314768483> ?p ?o ?g. }

• W2314768483 abstract "You have accessJournal of UrologyInfections/Inflammation/Cystic Disease of the Genitourinary Tract: Kidney & Bladder I1 Apr 2016MP24-16 PLASMA AND URINARY PHARMACOKINETICS OF A NOVEL, ORAL SHIP1 ACTIVATOR AQX-1125 IN FEMALE PATIENTS WITH INTERSTITIAL CYSTITIS J. Curtis Nickel, Robert Evans, Patrick Tam, Judy Toews, Lloyd Mackenzie, Heidi Biagi, and Stephen Shrewsbury J. Curtis NickelJ. Curtis Nickel More articles by this author , Robert EvansRobert Evans More articles by this author , Patrick TamPatrick Tam More articles by this author , Judy ToewsJudy Toews More articles by this author , Lloyd MackenzieLloyd Mackenzie More articles by this author , Heidi BiagiHeidi Biagi More articles by this author , and Stephen ShrewsburyStephen Shrewsbury More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.772AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES AQX-1125 is a novel SH2-containing inositol-5′-phosphatase 1 (SHIP1) activator previously demonstrated to modulate inflammation. Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic condition of unknown etiology, associated with inflammation of the bladder epithelium. The LEADERSHIP trial was a multicenter, randomized, double-blind, placebo-controlled, Phase 2 clinical trial investigating the ability of 200 mg AQX-1125 to reduce pain in female patients with IC/BPS in North America. Here we assess the extent of bladder exposure to AQX-1125 over 6 weeks with trough drug levels in plasma and urine. METHODS Blood and urine was collected after 28 and 42 days. Samples were analyzed for concentrations of AQX-1125 via HPLC-MS/MS methods and trough levels calculated. RESULTS PK samples where collected from 35 patients randomized to AQX-1125. The mean/geometric mean plasma concentrations were 252/211 and 225/162 ng/mL for Days 28 and 42, respectively. The mean/geometric mean urine concentrations were 49,863/34,450 and 33,396/22,934 ng/mL for Days 28 and 42, respectively, at least 140-fold higher than the corresponding plasma levels. The trough plasma concentrations are similar to, or exceed, those anticipated for efficacy from earlier clinical trials and pre-clinical studies. CONCLUSIONS The novel SHIP1 activator, AQX-1125 reaches the bladder of IC/BPS patients via both the bloodstream and the urine. The urinary route of elimination of AQX-1125 as parent compound may be an attractive property of the drug for IC/BPS. If once daily oral AQX-1125 proves effective in ameliorating symptoms of IC/BPS, both systemic and direct exposure of drug to the bladder may contribute to that response. This pharmacokinetic data supports continued development of AQX-1125 as an oral, once-daily therapy for IC/BPS. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e276 Advertisement Copyright & Permissions© 2016MetricsAuthor Information J. Curtis Nickel More articles by this author Robert Evans More articles by this author Patrick Tam More articles by this author Judy Toews More articles by this author Lloyd Mackenzie More articles by this author Heidi Biagi More articles by this author Stephen Shrewsbury More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2314768483 created "2016-06-24" @default.
• W2314768483 creator A5003930087 @default.
• W2314768483 creator A5017633258 @default.
• W2314768483 creator A5034445650 @default.
• W2314768483 creator A5034811772 @default.
• W2314768483 creator A5042018889 @default.
• W2314768483 creator A5054544330 @default.
• W2314768483 creator A5067498610 @default.
• W2314768483 date "2016-04-01" @default.
• W2314768483 modified "2023-10-16" @default.
• W2314768483 title "MP24-16 PLASMA AND URINARY PHARMACOKINETICS OF A NOVEL, ORAL SHIP1 ACTIVATOR AQX-1125 IN FEMALE PATIENTS WITH INTERSTITIAL CYSTITIS" @default.
• W2314768483 doi "https://doi.org/10.1016/j.juro.2016.02.772" @default.
• W2314768483 hasPublicationYear "2016" @default.
• W2314768483 type Work @default.
• W2314768483 sameAs 2314768483 @default.
• W2314768483 citedByCount "0" @default.
• W2314768483 crossrefType "journal-article" @default.
• W2314768483 hasAuthorship W2314768483A5003930087 @default.
• W2314768483 hasAuthorship W2314768483A5017633258 @default.
• W2314768483 hasAuthorship W2314768483A5034445650 @default.
• W2314768483 hasAuthorship W2314768483A5034811772 @default.
• W2314768483 hasAuthorship W2314768483A5042018889 @default.
• W2314768483 hasAuthorship W2314768483A5054544330 @default.
• W2314768483 hasAuthorship W2314768483A5067498610 @default.
• W2314768483 hasBestOaLocation W23147684831 @default.
• W2314768483 hasConcept C112705442 @default.
• W2314768483 hasConcept C121608353 @default.
• W2314768483 hasConcept C126322002 @default.
• W2314768483 hasConcept C126894567 @default.
• W2314768483 hasConcept C142724271 @default.
• W2314768483 hasConcept C204787440 @default.
• W2314768483 hasConcept C27081682 @default.
• W2314768483 hasConcept C2776235491 @default.
• W2314768483 hasConcept C2778508898 @default.
• W2314768483 hasConcept C2779478474 @default.
• W2314768483 hasConcept C29456083 @default.
• W2314768483 hasConcept C71924100 @default.
• W2314768483 hasConcept C77411442 @default.
• W2314768483 hasConcept C90924648 @default.
• W2314768483 hasConceptScore W2314768483C112705442 @default.
• W2314768483 hasConceptScore W2314768483C121608353 @default.
• W2314768483 hasConceptScore W2314768483C126322002 @default.
• W2314768483 hasConceptScore W2314768483C126894567 @default.
• W2314768483 hasConceptScore W2314768483C142724271 @default.
• W2314768483 hasConceptScore W2314768483C204787440 @default.
• W2314768483 hasConceptScore W2314768483C27081682 @default.
• W2314768483 hasConceptScore W2314768483C2776235491 @default.
• W2314768483 hasConceptScore W2314768483C2778508898 @default.
• W2314768483 hasConceptScore W2314768483C2779478474 @default.
• W2314768483 hasConceptScore W2314768483C29456083 @default.
• W2314768483 hasConceptScore W2314768483C71924100 @default.
• W2314768483 hasConceptScore W2314768483C77411442 @default.
• W2314768483 hasConceptScore W2314768483C90924648 @default.
• W2314768483 hasIssue "4S" @default.
• W2314768483 hasLocation W23147684831 @default.
• W2314768483 hasOpenAccess W2314768483 @default.
• W2314768483 hasPrimaryLocation W23147684831 @default.
• W2314768483 hasRelatedWork W1962507201 @default.
• W2314768483 hasRelatedWork W1966898087 @default.
• W2314768483 hasRelatedWork W1970781058 @default.
• W2314768483 hasRelatedWork W1987512841 @default.
• W2314768483 hasRelatedWork W2005938254 @default.
• W2314768483 hasRelatedWork W2035396100 @default.
• W2314768483 hasRelatedWork W2070170982 @default.
• W2314768483 hasRelatedWork W2110308314 @default.
• W2314768483 hasRelatedWork W2111351802 @default.
• W2314768483 hasRelatedWork W2126309436 @default.
• W2314768483 hasVolume "195" @default.
• W2314768483 isParatext "false" @default.
• W2314768483 isRetracted "false" @default.
• W2314768483 magId "2314768483" @default.
• W2314768483 workType "article" @default.